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AIDS Review
‘The world is in recession, but HIV/AIDS is not in reces-
sion,’ so blasted the trumpets from activists, scientists, 
and people affected with HIV/AIDS at the 5th Inter-
national AIDS Conference on HIV Pathogenesis, Treat-
ment and Prevention at Cape Town, South Africa, in July 
2009. The perceived backlash against HIV/AIDS and the 
threatened withdrawal of international support for HIV/
AIDS as well as for other disease-specific programmes 
was defiantly confronted by the 7000 or so delegates, 
justifiably angry at the way governments worldwide 
seem able to find billions of dollars to support failing 
banks but unable to find a few billion to save the lives of 
people affected with HIV/AIDS, tuberculosis (TB), and 
malaria in some of the poorest countries of the world. 
‘Towards Universal Access’
The September 2009 Progress Report on the scaling-up 
of HIV/AIDS interventions in the health sector acknowl-
edges the continuing challenge that the HIV epidemic 
poses for global health, with 33 million adults and 
children living with HIV and 2.7 million new infections 
in 2007.1 Nevertheless, despite the challenges and the 
shortfalls in the global response to the epidemic, un-
doubted progress has been made. 
At the end of 2008, more than 4 million (3.7–4.4 mil-
lion) people were receiving antiretroviral therapy (ART) 
in low- and middle-income countries, an increase of 
more than 1 million compared with the end of 2007 and 
a 10-fold expansion in 5 years. The greatest increase 
has been in sub-Saharan Africa where about 2.9 million 
(2.7–3.2 million) people were receiving ART at the end 
of 2008. The estimated coverage of ART in low- and 
middle-income countries reached 42% and coverage 
in sub-Saharan Africa was 44%. About 60% of adults 
receiving ART in reporting countries were women, who 
represent 55% of the people in need. In 2008, 38% 
(31%–47%) of children estimated to need ART glob-
ally had access. In sub-Saharan Africa, between 2007 
and 2008, the estimated number of children receiving 
ART increased from 158 000 to 225 000, with total 
coverage in children reaching about 35%. Retention 
on therapy is of concern, with rates reported at 75% at 
12 months and 67% at 24 months. Most of the attrition 
occurs early, in the first year of treatment, reflecting the 
fact that many people living with HIV (PLHIV) present 
late and die during the first few months of treatment. 
TB continues to be a leading cause of death in PLHIV. 
There were an estimated 1.37 million HIV-infected TB 
cases in 2007, of whom 456 000 died during anti-TB 
treatment.2 Collaborative HIV and TB activities need to 
improve. For example, in 2007, only 16% of notified TB 
patients knew their HIV status and only 100 000 (7.3%) 
co-infected TB patients were believed to have started 
ART, figures that are in desperate need of improvement 
to avert HIV- and TB-related deaths.
Access to services for preventing mother-to-child 
transmission in low- and middle-income countries 
continued to expand in 2008. Twenty one percent of 
pregnant women received an HIV test in 2008, up from 
15% in 2007, and 45% of HIV-infected pregnant wom-
en in the region received antiretroviral drugs to prevent 
mother-to-child transmission, up from 35% in 2007.1 
However, early infant diagnosis remains problematic, 
and in 41 reporting countries only 15% of children 
born to HIV-infected mothers were tested for HIV in the 
first 2 months of life. 
The availability and uptake of HIV testing and coun-
selling continued to increase in 2008. In 66 low- and 
middle-income countries with comparable data, the 
total number of health facilities providing HIV testing 
services increased from 25 000 in 2007 to 33 600 in 
2008.1 Population-based surveys conducted between 
2005 and 2008 showed that the proportion of people 
ever tested for HIV increased from 15% to 39%, largely 
as a result of provider-initiated HIV testing and counsel-
ling in healthcare facilities.  
New data on epidemiology and dynamics of 
the HIV epidemic in Africa
A recent review in the Lancet indicated the widespread 
existence of men who have sex with men (MSM) groups 
in sub-Saharan Africa and high rates of HIV infection.3 
However, because homosexuality is illegal in many 
countries and political and social hostility is endemic, 
the challenges in providing relevant HIV/AIDS informa-
tion and services are huge, but nevertheless need to be 
tackled if headway is to be made.
Many African countries with high HIV prevalence 
and low rates of male circumcision established policies 
in 2008 to scale-up male circumcision, although hard 
data on actual progress is difficult to find. Disappoint-
ingly, a well-conducted study in Uganda showed no 
reduction in risk of HIV transmission to female part-
ners of HIV-infected men who had been circumcised,4 
challenging previous observational studies reporting an 
association between male circumcision and reduced 
HIV infection in female partners. Although providing no 
direct benefit for the women, it is likely that women will 
benefit from male circumcision programmes as wide 
scale roll-out would lead to decreasing HIV prevalence 
in communities over 10–20 years. 
Universal HIV testing and immediate start of ART
Despite current best efforts, the annual number of new 
infections remains high and continues to outpace the 
number of people receiving ART. In January 2009, Africa Health  59 January 2010
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a radical approach was presented in the Lancet to 
controlling the HIV epidemic in high burden areas of 
sub-Saharan Africa.5 Using a mathematical model that 
included the case reproduction number (stochastic 
model), long-term dynamics of the HIV epidemic (de-
terministic transmission model), and data from South 
Africa as representative of a generalised heterosexual 
epidemic, a strategy was proposed of testing all adults 
for HIV every year and starting ART immediately after 
they are diagnosed HIV-positive. The authors claimed 
that this could reduce HIV incidence and mortality by 
95% in 10 years, and HIV prevalence to less than 1% 
within 50 years. The conclusion was that this approach 
merits further mathematical modelling, research, and 
broad consultation.
Not surprisingly, this proposal has caused a huge 
amount of discussion and controversy, not least of 
which is the argument that ART would be for public-
health benefits rather than individual patients’ benefits, 
particularly if the costs of toxicity and inconvenience 
outweigh the clinical benefits.6 In this regard, two large 
observational studies were published during 2009 from 
the industrialised world examining the benefits of early 
versus deferred ART on individual survival.7,8 Both ar-
ticles, examining a total of almost 40 000 HIV-infected 
patients from the USA and Europe, found that starting 
ART at CD4 counts of 350 cells/mL or higher was as-
sociated with a significant reduction in risk of death. 
This provides evidence that there is individual benefit to 
early ART start. The model of universal HIV testing and 
immediate start of ART needs to be taken seriously, and 
tested for efficacy, feasibility, safety, impact, and cost, 
with attention paid to operational aspects such as com-
munity acceptability, protection of human rights, safety, 
and acceptability of ART regimens, quality delivery 
systems and effective monitoring and reporting.
HIV vaccines
There was a seminal publication in October 2009 of a 
randomised controlled efficacy trial in Thailand evaluat-
ing a prime-boost HIV vaccine in 16 402 healthy men 
and women.9 ALVAC HIV was the prime vaccination 
(consisting of a canarypox viral vector and genetically 
engineered versions of HIV env, gag, and pro genes, 
and designed to elicit a T-cell-mediated response). AID-
SVAX B/E was the boost vaccine (consisting of recom-
binant gp120 spike proteins derived from HIV subtypes 
B and E, and designed to induce antibody-mediated 
immunity). Immunisation required six injections over 6 
months, four with ALVAC HIV and two with AIDSVAX 
B/E at the same time as the last two ALVAC HIV injec-
tions. In a modified intention to treat analysis there was 
a relative reduction of infection of 31.2% (95% con-
fidence interval (CI), 1%–51%) in vaccine recipients. 
Vaccination did not affect the degree of viraemia or the 
CD4 cell count in those in whom HIV-1 infection was 
subsequently diagnosed. 
For those working or keeping up-to-date with vaccine 
trials, this was a surprising result as the two vaccine 
candidates, when evaluated independently, had per-
formed poorly in previous clinical trials. Many ques-
tions also remain as to the wide confidence intervals 
around efficacy, the duration of efficacy, the protective 
effects in high-risk groups, and whether this vaccine 
geared towards the HIV B and E subtypes that circulate 
in Thailand would be appropriate in other settings, 
especially in Africa where subtype C reigns supreme. 
Nevertheless, it is the first of the HIV vaccine studies 
that offers a glimmer of hope in a field previously lit-
tered with disappointments. 
Linking HIV/AIDS support with health systems
The debate and discussion continues about the relative 
merits of supporting disease-specific programmes such 
as HIV/AIDS or primary healthcare systems, although 
perhaps with less polarisation than 12 months ago. The 
US President’s Emergency Plan for AIDS Relief (PEPFAR) 
and the Global Fund to fight AIDS, Tuberculosis and 
Malaria (GFATM) are major global health initiatives that 
have transformed the landscape of global health.10 Rich-
ard Horton, Editor of the Lancet, argues eloquently that 
these financing initiatives now need to broaden their 
mission and include additional health goals such as ma-
ternal, newborn, and child health.10 This has to be the 
right approach so that we move towards 2015 knowing 
that globally we are pooling and committing our re-
sources to tackle the three important health-related Mil-
lennium Development Goals, MDG 4,5, and 6.  
Anthony D Harries  
International Union against Tuberculosis and Lung Disease 
Paris, France and London School of Hygiene and Tropical 
Medicine, London, UK;
and Rony Zachariah, Medecins sans Frontieres, 
Medical Department, Operational Research Unit
Brussels Operational Centre, Luxembourg
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Strongyloidiasis
A recent review article in the Transactions of the Royal 
Society of Tropical Medicine and Hygiene draws atten-
tion to the rather forgotten condition of strongyloidiasis 
– human infection with the nematode work – Strongy-
loides stercoralis.1 This is a soil-transmitted helminth – 
part of a group of infections which are on the accepted 
list of ‘neglected tropical diseases’.  Indeed, the authors 
refer to strongyloidiasis in the title of their article as ‘the 
most neglected of the neglected tropical diseases’.
Strongyloidiasis is widely distributed in the tropics 
and sub-tropics, and also occurs in some temperate 
zones. The worm is highly advanced, with life cycle 
adaptions to help survival. There is a free-living sexual 
cycle in the soil, which can persist without the need for 
human infection. Soil larvae can, however, infect man 
by penetration of intact skin (usually of the feet). Filari-
form larvae travel to the lungs, migrate up the bronchial 
tree and are swallowed. In the duodenum and proximal 
jejunum, the larvae develop into adult females which 
produce eggs. These eggs develop into rhabditiform 
larvae, which are passed in the stool from where they 
enter the soil and the free-living cycle. However, 
rhabditiform larvae can ‘auto-infect’ the human host by 
penetrating the rectal mucosa or peri-anal skin. These 
larvae then migrate to the lungs, to continue the human 
cycle without the need for new external infection. The 
process of auto-infection explains why strongyloidiasis 
can continue indefinitely even when infected patients 
move out of areas of endemic infection. This has impor-
tant implications for travellers in the tropics who return 
to their homes in temperate regions.
The clinical presentation of Strongyloides infections 
is highly variable, and many infections can be quite 
asymptomatic. Acute infections can cause diarrhoea 
and/or abdominal pain. Occasionally the diarrhoea can 
be bloody (‘dysenteric strongyloidiasis’), and sometimes 
may become long-standing and associated with malab-
sorption and weight loss (a ‘sprue-like’ syndrome). In 
chronic auto-infective infections, abdominal symptoms 
are less common, and a more frequent feature is the 
‘larva currens’ rash, sometimes known as ‘creeping 
eruption’. This represents the migration of auto-infecting 
larvae, and consists of an urticarial wheal surrounded 
by an erythematous flare, which rapidly moves around 
the central body areas (trunk, shoulders, or buttocks).  
The rash comes and goes, often with weeks or months 
between attacks.
A final, but very serious, clinical manifestation of 
strongyloidiasis, is known as ‘hyperinfection’. If an 
infected host suffers immune suppression (of any cause 
– but steroid drug treatment is the most common), then 
larvae can migrate outside the bowel to the peritoneum, 
liver, lungs, and central nervous system. Patients often 
present with Gram-negative septicaemia and shock. 
Diagnosis is often missed and the mortality is high.
Because the presentation of strongyloidiasis is so 
variable, a high degree of diagnostic suspicion is needed.  
Demonstration of typical larvae on stool microscopy 
confirms the diagnosis, but larval excretion is often 
intermittent and even three negative stool examinations 
does not exclude the diagnosis. Blood eosinophilia is 
often present, and if available modern ELISA or PCR 
serological tests are helpful. The treatment of choice is 
now ivermectin 200 mg/kg (either single treatment, or 
daily for 3 days). Alternatively, albendazole (400 mg 
twice daily for 3 days) can be used. Treatment of the 
hyperinfection syndrome is difficult – full supportive 
treatment including fluids, antibiotics, etc should be 
given, as well as anthelmintic drugs as above. Some-
times, however, there is intestinal ileus and oral drugs 
cannot be given. A veterinary preparation of ivermectin 
is available sometimes, and a single subcutaneous dose 
of 12 mg has been reported to have been successful. 
As mentioned, strongyloidiasis can occur in temperate 
zones. There is low-grade endemicity in the southern 
states of the USA, and some parts of Europe. In Britian, 
chronic auto-infective Strongyloides infections have 
been especially diagnosed in former Far East prison-
ers of war (POWs) of the Japanese during World War 
II. These infections usually started in the prison camps 
of the Thailand jungles and have persisted for decades 
afterwards in the UK. Two occurrences of fatal hyper-
infection have been recorded in this group of men.2
The message for doctors in Africa is to increase 
awareness of this variably presenting infection. More 
widespread use of mass treatment for soil-transmitted 
helminths will help with control, as will encouragement 
of the use of footwear (especially in highly prelevant 
areas). Patients who are likely to need steroid drugs (for 
example asthmatic patients) should receive particular 
attention – probably with annual albendazole, or regu-
lar stool microscopy.
Neuroschistosomiasis
Strongyloides stercoralis is not the only worm that can 
persist long-term in infected hosts who have left the 
endemic area. A recent case report concerns a South 
African man who presented with Schistosoma mansoni 
infection over 20 years after likely exposure (the patient 
had moved to New Zealand).3 He presented with acute 
urinary retention and sensory signs and symptoms in his 
legs. He had a past history of urinary schistosomiasis 
as a child. Investigations showed a cerebrospinal fluid 
(CSF) lymphocytocis, swelling of the conus medulla-
ris on magnetic resonance imaging (MRI) scanning, 
strongly positive schistosomal serology, and eggs of 
S mansoni in the faeces. A diagnosis of schistosomal 
myeloradiculopathy was made and he was treated 
with high-dose intravenous methylprednisolone for 5 
days with oral praziquantel for the first 2 days. Sensory 
symptoms initially worsened and he was given a further 
course of intravenous steroids, following which he im-
proved and eventually made a complete recovery.
Schistosomiasis has been previously reported as 
surviving for up to 30 years, and a distant travel his-
tory is important if the diagnosis of infection is to be 
considered.  The case also demonstrates the importance 
of neurological presentations of this condition. Eggs can 
reach the spinal cord either by embolisation, or due to 
migration of adult worms. In many developing countries, 
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MRI scanning and efficient serological tests are not 
available. Eggs may not be present in the stool, and 
the diagnosis may have to be clinical. In areas of high 
endemicity, patients presenting with cord syndromes 
(especially urinary retention and/or neurological signs 
and symptoms in the legs) for no obvious cause, should 
be considered as having potential neuroschistosomiasis.
Prompt treatment is vital, as otherwise permanent 
neurological damage may result. Praziquantel is the 
drug of choice, but steroids must also be used to reduce 
cord swelling.
Tight blood pressure control
Hypertension is very common in Africa, and is a major 
risk factor for stroke.  It is known that adequate treat-
ment of hypertension reduces the risk of stroke and 
other complications, but it is not certain what ideal 
‘target’ blood pressure (BP) levels should be for those on 
treatment.  In type 2 diabetes,  there is now very good 
evidence that tight BP control (systolic BP <130 mmHg) 
greatly improves outcome in terms of morbidity and 
mortality. A study has recently been published which 
suggests that the same applies for non-diabetic patients.4
The study was a randomised multi-centre study from 
Italy of 1111 non-diabetic adult hypertensive patients.  
They were randomised to have their systolic BP lowered 
to <140 mmHg (standard control) or <130 mmHg (tight 
control). Patients were followed for 2 years, and as this 
was too short a period to assess mortality effects, the 
main endpoint was electrocardiographic (ECG) left ven-
tricular hypertrophy (LVH).  This occurred in 17.0% of 
those on standard control, and 11.4% of those on strict 
control (p=0.013).
Clearly, this was not a long-term outcome study, but 
nevertheless it lends strong support to the beneficial 
effects of strict BP control in non-diabetic as well as 
diabetic hypertensive patients.  A target of <130/80 
should now be regarded as ideal. 
Professor Geoff Gill
Liverpool School of Tropical Medicine and
University Hospital Aintree, UK
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Paediatrics Review
Enterobius vermicularis: not always benign
Enterobius vermicularis (EV) is an extremely common 
gut parasite which is usually asymptomatic or may 
cause mild perianal irritation and pruritus. Peak preva-
lence rate is at 5–9 years. It is considered to be more 
common in temperate than tropical areas. Possible 
reasons include infrequent washing and change of un-
derclothes in lower socio-economic groups, especially 
in winter.
When EV ova are ingested the larvae are released 
from the eggs by digestive enzymes in the duodenum 
and the adult worms move to the distal ileum, caecum, 
and ascending colon where they mate.1 The gravid 
female worms migrate towards the ano-rectal region 
and lay their eggs on the perianal skin usually at night 
and die within a few hours. The life cycle is completed 
through auto-infection by contaminated fingers or fomites 
or when larvae migrate back into the rectum and gastro-
intestinal tract where they mature and mate. 
Complications arise from granulomatous reaction to 
the eggs or worms which are lodged in ectopic sites. In 
girls they may be associated with urinary tract infection 
and vaginal discharge. In adolescent girls and women 
the worms may migrate up the genital tract and cause 
disease of the vulva, vagina, uterus, and fallopian tubes 
resulting in salpingo-oophoritis.2–5 The worms may 
reach the peritoneum and produce chronic inflamma-
tion and pelvic pain or a generalised peritonitis. Access 
to the genital tract for EV explains why disease due to 
ectopic worms is more common in females.2
Other ways the worms may reach the peritoneum 
are through a perforated appendix or bowel,6 during 
surgery or because of carcinoma.3 The liver, spleen, and 
kidney may be affected by migration of the worms in 
the peritoneum. EV is detected in around 2% of appen-
dices excised electively or for appendicitis.7 
One of the commonest serious complications is 
enterocolitis.6,8 Usually this is associated with heavy 
infection by EV. Damage to the gut mucosa due to 
coincidental infection may allow EV larvae or immature 
worms to invade the bowel wall.1,9 Involvement of the 
ileum and the proximal colon may produce symptoms 
and colonoscopic features of inflammatory bowel dis-
ease (IBD).9 Involvement of the proximal small intestine 
has resulted in malabsorption syndrome; the thickened 
bowel wall was detected on both barium meal and 
CT scan.10 Other reports have also documented CT 
evidence of thickening of the walls of the ileum and 
caecum associated with EV infection. Histology demon-
strated intense eosinophilic infiltration. Another report 
described gangrenous jejunum with mesenteric nodes 
and transmural eosinophil and polymorphonuclear infil-
tration on histology.
Additional ectopic sites for EV include the lungs, 
presumably through embolic blood spread, or through 
migration down the trachea,2 and cerebrospinal fluid 
(CSF). Direct contamination of the external auditory 
meatus, nasal mucosa and conjuntiva, presumably by 
fingers contaminated by EV larvae, is described. An al-
lergic rash which responded to treatment of EV has also 
been reported.10 Interestingly, despite the peak preva-
lence of EV being in the pre-pubertal period most of the 
serious complications have been described in adults. 
Although this is likely to be due to its predominance in January 2010 62  Africa Health
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women, it could also possibly be due to an exaggerated 
hypersensitivity reaction to ova/worms in ectopic sites 
which might be more likely to occur in adolescents and 
adults in whom the immune system is more mature than 
in younger children.
A report from Alder Hey Children’s Hospital, Liv-
erpool has increased our knowledge about intestinal 
disease related to EV in children.11 A retrospective study 
of all children in whom colonoscopy was performed 
over a 3-year period is described. Most of the patients 
presented with symptoms suggestive of IBD, particu-
larly rectal bleeding. Of 180 patients, EV was detected 
in 31cases (17.2%) and complete data were available 
for 21 of these. Symptoms had been present for a time 
period ranging from 2 weeks to 5 years. No patient had 
perianal symptoms. Only two had a peripheral eosino-
philia. In 20 patients from whom a saline rectal swab 
was taken, all were negative for EV. In 21 of the 26 
patients there was histological evidence of non-specific 
colitis, vis, shallow mucosal ulcerations with segmental 
subepithelial haemorrhages, eosinophil infiltration, and 
mild focal inflammation. All were treated with meben-
dazole and 83% had a clinical response over a follow 
up period of 1–5 years. None of the patients developed 
IBD.
As EV is such an ubiquitous intestinal helminth the 
detection of worms in the gut or eggs on the anus may 
be coincidental, thus histological evidence is important. 
In ectopic sites necrotic ova are detected more often 
than the female worm but an ectopic gravid worm is 
likely to cause a larger immunological reaction.2 There 
is usually evidence of a chronic granuloma with vari-
able numbers of plasma cells, histiocytes, lymphocytes, 
eosinophils, and foreign body giant cells with surround-
ing fibrosis.2 Eosinophils are the most constant feature. 
Blood eosinophilia is common but is not necessary 
for the diagnosis. For detection of intestinal infection, 
worms may be seen on proctoscopy or colonoscopy, 
however, this depends on the experience of the endos-
copist and also on the level of infection. Saline rectal 
swabs may be used or adhesive tape may be applied to 
the anus in the morning. If the latter is done once, the 
positivity rate is only 5–10%; this rises to over 90% if 
the procedure is undertaken for 5 consequtive days.1 
Ova may also be detected from swabs taken from under 
the fingernails of patients.
Response to treatment (albendazole 400 mg or 
mebendazole 100 mg, one dose repeated in 2 weeks) is 
important for confirmation of the diagnosis. However, 
EV infection of the female genitals may be associ-
ated with infertility and chronic pelvic pain despite 
treatment.4,5The latter may be a form of autoimmunity, 
where there is on-going reaction to the dead ova/
worms, and may require drugs for immune modification.5
Dientamoeba fragilis is a flagellate which was first 
described in 1918. It is associated with acute or chronic 
gastrointestinal symptoms including abdominal pain, 
persistent diarrhoea, allergic colitis, flatulence, anorex-
ia, and weight loss.12 Because it has no resistant cystic 
stage it is considered that the trophozoites are unlikely 
to exist outside the human host. It is thought that trans-
mission may occur via the ova of EV. Thus, this parasite 
could in some circumstances be responsible for some of 
the symptoms associated with EV. However, more inves-
tigation is required to substantiate this theory.
In conclusion, EV can sometimes cause more than 
anal pruritus. Unfortunately, it has low priority for re-
search in both developing and industrialised countries. 
Prospective studies are required to investigate the role 
of EV in non-specific colitis in children and also its as-
sociation with D fragilis. In adolescent girls and women 
EV should be considered in the aetiology of chronic 
pelvic pain. In those in whom EV is demonstrated to 
be the likely cause, and in whom neither antiparasitic 
treatment nor surgery is of benefit, the role of immune 
modification treatment should be considered.5
J B S Coulter
Honorary Clinical Lecturer in Tropical Child Health
Liverpool School of Tropical Medicine, UK
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